Tumor necrosis factor-alpha: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett No edit summary |
||
| Line 5: | Line 5: | ||
* TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> Etanercept is used for the treatment of autoimmune diseases such as [[ankylosing spondylitis]].<ref name="pmid11986408">{{cite journal |author=Gorman JD, Sack KE, Davis JC |title=Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha |journal=N. Engl. J. Med. |volume=346 |issue=18 |pages=1349–56 |year=2002 |month=May |pmid=11986408 |doi=10.1056/NEJMoa012664 |url=http://content.nejm.org/cgi/content/full/346/18/1349 |issn=}}</ref> | * TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> Etanercept is used for the treatment of autoimmune diseases such as [[ankylosing spondylitis]].<ref name="pmid11986408">{{cite journal |author=Gorman JD, Sack KE, Davis JC |title=Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha |journal=N. Engl. J. Med. |volume=346 |issue=18 |pages=1349–56 |year=2002 |month=May |pmid=11986408 |doi=10.1056/NEJMoa012664 |url=http://content.nejm.org/cgi/content/full/346/18/1349 |issn=}}</ref> | ||
* Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{MedMaster|Infliximab}}</ref> | * Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{MedMaster|Infliximab}}</ref> | ||
===Adverse effects=== | |||
Tumor necrosis factor inhibitors increase susceptibility to serious infections.<ref name="urlFDA MedWatch - 2008 Safety Alerts for Human Medical Products">{{cite web |url=http://www.fda.gov/medwatch/safety/2008/safety08.htm#TNF2 |title=FDA MedWatch - 2008 Safety Alerts for Human Medical Products |author=Anonymous |authorlink= |coauthors= |date=2008 |format= |work= |publisher= U.S. Food and Drug Administration |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 11:30, 4 September 2008
In medicine, tumor necrosis factor-alpha is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to tnf-beta (lymphotoxin), but they share TNF receptors.[1]
Tumor necrosis factor inhibitors
- TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.[2] Etanercept is used for the treatment of autoimmune diseases such as ankylosing spondylitis.[3]
- Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.[4]
Adverse effects
Tumor necrosis factor inhibitors increase susceptibility to serious infections.[5]
References
- ↑ Anonymous (2024), Tumor necrosis factor-alpha (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Template:MedMaster
- ↑ Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
- ↑ Template:MedMaster
- ↑ Anonymous (2008). FDA MedWatch - 2008 Safety Alerts for Human Medical Products. U.S. Food and Drug Administration.